- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
FDA approves ULTOMIRIS® for treatment of rare blood disorder
The US Food and Drug Administration (FDA) has given approval for the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to treat paroxysmal nocturnal hemogloinuria in children and teenagers.
The US Food and Drug Administration has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) from Alexion Pharmaceuticals, Inc. for the treatment of paroxysmal nocturnal hemogloinuria, a rare blood disorder, in children aged 1 month and older.1 The medication was approved for use in adults in 2018 and is the standard of care for treatment. Ravulizumab-cwvz is a long-acting C5 inhibitor.
The approval was the result of findings from an interim Phase 3 trail that showed that the medication was effective in accomplishing complete C5 complement inhibition through 26 weeks in children and adolescents. During the course of the trial, there were no reported severe adverse events related to the treatment. None of the participants stopped treatment during the initial evaluation period or had breakthrough hemolysis. The findings of the trial indicate that both safe and efficacy in the pediatric population are consistent with that found in adults.
Alexion Pharmaceuticals, Inc. will make the drug immediately available for pediatric patients.
Reference
1. Alexion Pharmaceuticals. Alexion announces FDA approval of ULTOMIRIS® (ravulizumab-cwvz) for children and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). Published June 7, 2021. Accessed June 8, 2021. https://ir.alexion.com/news-releases/news-release-details/alexion-announces-fda-approval-ultomirisr-ravulizumab-cwvz
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.
